New Data on Needle Free Epinephrine Spray Presented at ACAAI 2024
A summary of new data presented at the 2024 American College of Allergy, Asthma & Immunology Annual Scientific Meeting.
© ARS Pharmaceuticals, Inc.
- Title: Cardiovascular Safety of Intramuscular and Intranasal Epinephrine Administration
- Objective: Characterize the pharmacokinetic and pharmacodynamic relationship for different routes of administration.
- See the poster
- Title: Blood Pressure and Pulse Rate without Concomitant Epinephrine Increase
- Objective: Analysis of changes in blood pressure, heart rate, and endogenous epinephrine levels following the induction of allergic rhinitis and anaphylactic symptoms in two clinical trials.
- See the poster
- Title: Human Factor Study on Two-Dose Case for neffy
- Objective: To validate that the intended population could administer neffy correctly in the event of a simulated severe allergic reaction
- See the poster
- Title: Significant Differences in Pharmacokinetics Among Epinephrine Products
- Objective: Review recent data that have demonstrated notable pharmacokinetic differences among different delivery routes.
- See the poster
- Title: Pharmacokinetics And Pharmacodynamics Following Repeat Dosing of ARS-1 versus Intramuscular Injection During Allergic Rhinitis
- Objective: Investigate repeated doses of neffy in patients with seasonal allergic reaction (SAR) following a nasal allergen challenge (NAC).
- See the poster
- Title: Real-World Data on Pediatric Food Allergy Patients
- Objective: Evaluate pediatric response to neffy. To date, no clinical trials have been conducted to support pediatric doses of epinephrine injection products for the treatment of severe allergic reactions.
- See the poster
- Title: HCP Interest in Self-Administered Intranasal Epinephrine
- Objective: Measure health care provider (HCP) awareness, perceptions, and prescribing of existing treatments for patients with Type 1 allergic reactions, including anaphylaxis, and to establish baseline HCP awareness and perceptions of neffy.
- See the poster
ARS Pharmaceuticals is presenting new data October 25 on the first needle-free epinephrine nasal spray (neffy) for treating Type I allergic reactions, at the 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting.
These presentations will showcase a number of posters covering topics such as cardiovascular safety, human factor research for emergency readiness, and real-world data in pediatric patients.
The above slideshow features a snapshot of the presentations being featured at the ACAAI meeting, with links to view the posters.
